Aspect Biosystems Partners With Merck, GSK, and McGill University to Enable Development of Immuno-Oncology Therapeutics
This project will leverage Aspect Biosystems’ microfluidic 3D bioprinting platform to develop highly physiological, high-throughput tissues for the accurate and predictive screening of immuno-therapeutics targeting difficult-to-treat cancers such as triple… Read More


